Theramir launches MiRACULOUS project for malignant wound care
09:14 - 22 January 2024
Cyprus-based Theramir Ltd has announced the launch of its “MiRACULOUS” project which aims to create technology that will help treat malignant wounds affecting at least 15% of advanced oncology patients.
“We are excited to announce that today marks the launch of our new project, “MiRACULOUS”, set to redefine the landscape of malignant and chronic wound therapeutics,” the company said in an announcement following the project's kick-off meeting.
According to the Project Overview, MiRACULOUS technology aims to revolutionise the management of malignant wounds. “Malignant wounds are a devastating complication in cancer affecting at least 15% of advanced oncology patients,” the company explained. “In a landscape where current therapeutic options often focus on symptom alleviation within a palliative care model, our microRNA-based nanotechnology in combination with molecular engineered collagen biomaterials and natural extracts offers a compelling remedy. It's not just about alleviating symptoms – it's about introducing therapeutic solutions that significantly enhance the quality of patients‘ lives.”
At Theramir Ltd, we recognize the urgent need for innovative solutions in the field of malignant wounds. MiRACULOUS is the result of collaborative efforts, bringing together a team of dedicated professionals and breakthrough start-ups Promed Bioscience, RSL Revolutionary Labs Ltd, and Vet Ex Machina LTD, who according to Theramir are ready to push the boundaries of what's possible in malignant wound care. “Our mission is to create a future where patients have access to advanced, effective and compassionate therapeutic options.”
MiRACULOUS is funded by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument, through the Research and Innovation Foundation with a budget of €200,000 Euros. Project Coordinator is Dr Marianna Prokopi-Demetriades and host organisation is Theramir Ltd.
According to its website, Theramir brings together a team of research entrepreneurs with significant experience in the discovery, development and commercialisation of innovative cancer pharmaceuticals.